Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1.
about
Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative dataNovel therapies for cutaneous T-cell lymphoma: what does the future hold?Targeted therapies for cutaneous T-cell lymphomas.Sézary syndrome: old enigmas, new targets.Role of dysregulated cytokine signaling and bacterial triggers in the pathogenesis of Cutaneous T Cell Lymphoma.
P2860
Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1.
@en
Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1.
@nl
type
label
Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1.
@en
Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1.
@nl
prefLabel
Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1.
@en
Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1.
@nl
P2093
P2860
P356
P1433
P1476
Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1.
@en
P2093
J A Caesar
R C T McKenzie
S J Whittaker
T J Mitchell
P2860
P2888
P304
P356
10.1038/LEU.2011.198
P577
2011-08-05T00:00:00Z
P6179
1026743636